FDA Adds “Consultation Meetings” To Patient-Focused Drug Development Effort
This article was originally published in The Pink Sheet Daily
The agency is seeking patient community input on process issues related to holding 20 meetings on disease-specific areas over the next five years under PDUFA V. FDA has proposed 39 medical conditions that could be considered for those disease-specific meetings.
You may also be interested in...
The Bone, Reproductive and Urologic Drugs Advisory Committee will consider endpoints, clinical trial designs and other issues related to development in the disease.
In the fourth meeting conducted under FDA’s patient-focused drug development initiative, dozens of narcoleptics talked about the symptoms they would like new therapies to address. However, some patients said new drugs should go beyond providing mere symptom relief and target the root of the condition.
The two-day workshop on chronic fatigue syndrome/myalgic encephalomyelitis elicited extensive, detailed testimony from patients about their symptoms and current treatment that will inform FDA policy, but it also underscored the challenges of explaining FDA’s regulatory processes to the patient community.